MedTrace Logo

A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors

NCT00276913 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-02-03

No results posted yet for this study

Summary

Primary Objectives:

* To determine the safety, toxicity and the maximum tolerated dose (MTD) of intravenous STA-5312 when administered weekly (3 of 4 weeks) to subjects with advanced or metastatic solid tumors.
* To determine the pharmacokinetics of STA-5312.

Secondary Objective:

• To assess antitumor activity of STA-5312 administration.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

STA-5312

Sponsors & Collaborators

  • Synta Pharmaceuticals Corp.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276913 on ClinicalTrials.gov